EP4011898B8 - 3-hydroxy-5-pregnane-20-one derivative and use thereof - Google Patents

3-hydroxy-5-pregnane-20-one derivative and use thereof

Info

Publication number
EP4011898B8
EP4011898B8 EP20852240.9A EP20852240A EP4011898B8 EP 4011898 B8 EP4011898 B8 EP 4011898B8 EP 20852240 A EP20852240 A EP 20852240A EP 4011898 B8 EP4011898 B8 EP 4011898B8
Authority
EP
European Patent Office
Prior art keywords
pregnane
hydroxy
derivative
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
EP20852240.9A
Other languages
German (de)
English (en)
French (fr)
Other versions
EP4011898B1 (en
EP4011898A1 (en
EP4011898A4 (en
Inventor
Fei Liu
Gang Wu
Chenggang LIN
Xiaobo Wang
Xiaoqiang Wang
Ruzhi WANG
Bin Zhu
Kongchao XU
Xiaoyan Sun
Jun Cai
Lin Wang
Weihua JIANG
Minqiang ZHENG
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
TWi Biotechnology Inc
Original Assignee
TWi Biotechnology Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by TWi Biotechnology Inc filed Critical TWi Biotechnology Inc
Priority to RS20260316A priority Critical patent/RS67876B1/sr
Publication of EP4011898A1 publication Critical patent/EP4011898A1/en
Publication of EP4011898A4 publication Critical patent/EP4011898A4/en
Publication of EP4011898B1 publication Critical patent/EP4011898B1/en
Application granted granted Critical
Publication of EP4011898B8 publication Critical patent/EP4011898B8/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J7/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms
    • C07J7/0005—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21
    • C07J7/001—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by a keto group
    • C07J7/0015—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by a keto group not substituted in position 17 alfa
    • C07J7/002—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by a keto group not substituted in position 17 alfa not substituted in position 16
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • C07J41/0033—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
    • C07J41/005—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 the 17-beta position being substituted by an uninterrupted chain of only two carbon atoms, e.g. pregnane derivatives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J43/00—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton
    • C07J43/003—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton not condensed
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J7/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Anesthesiology (AREA)
  • Addiction (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
EP20852240.9A 2019-08-09 2020-08-07 3-hydroxy-5-pregnane-20-one derivative and use thereof Active EP4011898B8 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
RS20260316A RS67876B1 (sr) 2019-08-09 2020-08-07 Derivat 3‑hidroksi‑5‑pregnan‑20‑ona i njegova upotreba

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN201910736020.8A CN112341511A (zh) 2019-08-09 2019-08-09 3-羟基-5-孕烷-20-酮衍生物及其用途
PCT/CN2020/107965 WO2021027744A1 (zh) 2019-08-09 2020-08-07 3-羟基-5-孕烷-20-酮衍生物及其用途

Publications (4)

Publication Number Publication Date
EP4011898A1 EP4011898A1 (en) 2022-06-15
EP4011898A4 EP4011898A4 (en) 2023-09-20
EP4011898B1 EP4011898B1 (en) 2026-01-07
EP4011898B8 true EP4011898B8 (en) 2026-02-18

Family

ID=74366997

Family Applications (1)

Application Number Title Priority Date Filing Date
EP20852240.9A Active EP4011898B8 (en) 2019-08-09 2020-08-07 3-hydroxy-5-pregnane-20-one derivative and use thereof

Country Status (11)

Country Link
US (1) US20220289788A1 (pl)
EP (1) EP4011898B8 (pl)
JP (1) JP7785674B2 (pl)
CN (2) CN112341511A (pl)
DK (1) DK4011898T3 (pl)
ES (1) ES3060711T3 (pl)
FI (1) FI4011898T3 (pl)
PL (1) PL4011898T3 (pl)
PT (1) PT4011898T (pl)
RS (1) RS67876B1 (pl)
WO (1) WO2021027744A1 (pl)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114907436A (zh) * 2021-02-08 2022-08-16 南京诺瑞特医药科技有限公司 3-羟基-5-孕烷-20-酮衍生物的晶型及其制备方法和用途
CN115806579B (zh) * 2021-09-14 2025-10-24 南京迈诺威医药科技有限公司 一种水溶性别孕烷醇酮衍生物及其制备方法和用途
IT202100030671A1 (it) 2021-12-03 2023-06-03 Ind Chimica Srl PROCESSO PER LA PREPARAZIONE DI (3a,5a)-20-OSSOPREGNAN-3-IL GLICIL-L-VALINATO CLORIDRATO
CN117801047B (zh) * 2023-01-19 2024-12-20 北京华睿鼎信科技有限公司 神经甾体衍生物及其用途
WO2024188169A1 (zh) * 2023-03-10 2024-09-19 南京迈诺威医药科技有限公司 别孕烷醇酮衍生物的盐型、多晶型及其制备方法和用途

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5232917A (en) * 1987-08-25 1993-08-03 University Of Southern California Methods, compositions, and compounds for allosteric modulation of the GABA receptor by members of the androstane and pregnane series
DK0752860T3 (da) * 1994-02-14 2000-11-13 Euro Celtique Sa Androstaner og pregnaner til allosterisk modulering af GABA-receptor
CA2582231A1 (en) * 2004-09-29 2006-10-19 Hollis-Eden Pharmaceuticals, Inc. Steroid analogs and uses
AU2009219230A1 (en) * 2008-02-26 2009-09-03 Emory University Steroid analogues for neuroprotection
GB2470700B (en) * 2008-03-25 2012-08-08 Univ Maryland C-17 heteroaryl steroidal CYP17 inhibitors
CN101585862B (zh) * 2008-05-20 2014-12-17 梅克芳股份公司 甾族化合物
WO2010088409A2 (en) * 2009-01-30 2010-08-05 Emory University Methods of neuroprotection using neuroprotective steroids and a vitamin d
BR112012017136B1 (pt) * 2010-01-14 2021-05-25 Umecrine Mood Ab composição farmacêutica compreendendo 3-beta-hidróxi5-alfa-pregnan-20-ona, colesterol e uma mistura de acilgliceróis, método para preparar dita composição farmacêutica, bem como usos da mesma para o tratamento ou prevenção de condições do sistema nervoso central e para cessar a anestesia induzida por esteroide
WO2011120044A1 (en) * 2010-03-26 2011-09-29 Duke University Conjugated neuroactive steroid compositions and methods of use
US9670247B2 (en) * 2012-07-02 2017-06-06 The University Of Kansas Contraceptive agents
WO2015081170A2 (en) * 2013-11-26 2015-06-04 Systamedic Inc. Ganaxolone derivatives for treatment of central nervous systems disorders
CN103772469A (zh) * 2014-02-21 2014-05-07 中国科学院上海有机化学研究所 一种含有动物固醇和天然精氨酸结构片段的合成阳离子脂质、合成方法及其应用
JOP20200195A1 (ar) * 2014-09-08 2017-06-16 Sage Therapeutics Inc سترويدات وتركيبات نشطة عصبياً، واستخداماتها
CN108148106A (zh) * 2016-12-05 2018-06-12 江苏恩华络康药物研发有限公司 一类水溶性别孕烯醇酮衍生物及其用途
US20200276211A1 (en) * 2017-11-28 2020-09-03 Viewpoint Therapeutics, Inc. Compounds for treating near vision disorders
CN108517001A (zh) * 2018-05-17 2018-09-11 江苏恩华络康药物研发有限公司 水溶性别孕烯醇酮衍生物及其用途
CN109776647B (zh) * 2019-02-14 2021-09-17 烟台大学 具有抗炎活性的Pyxinol酯化衍生物及其制备方法和应用
CZ309617B6 (cs) * 2019-04-05 2023-05-24 Ústav organické chemie a biochemie AV ČR, v. v. i 3α5ß-Neuroaktivní steroidy pro léčbu epilepsie a záchvatových onemocnění

Also Published As

Publication number Publication date
JP7785674B2 (ja) 2025-12-15
EP4011898B1 (en) 2026-01-07
CN112341511A (zh) 2021-02-09
EP4011898A1 (en) 2022-06-15
WO2021027744A1 (zh) 2021-02-18
ES3060711T3 (en) 2026-03-27
PL4011898T3 (pl) 2026-05-11
DK4011898T3 (da) 2026-03-09
JP2022545047A (ja) 2022-10-24
PT4011898T (pt) 2026-03-25
CN114206899A (zh) 2022-03-18
CN114206899B (zh) 2025-09-05
RS67876B1 (sr) 2026-04-30
EP4011898A4 (en) 2023-09-20
FI4011898T3 (fi) 2026-02-24
US20220289788A1 (en) 2022-09-15

Similar Documents

Publication Publication Date Title
EP3917517A4 (en) CONNECTIONS AND USES THEREOF
EP3752612A4 (en) MODIFIED COMPOUNDS AND USES THEREOF
EP4037670A4 (en) 5-FLUORONICOTINAMIDE DERIVATIVES AND USES THEREOF
EP3971190A4 (en) HETEROCYCLICALLY CONDENSED PYRIMIDIDE DERIVATE AND USE THEREOF
EP4006048A4 (en) NEW HMMW MICROPEPTIDE AND ITS APPLICATION
PL4011898T3 (pl) Pochodna 3-hydroksy-5-pregnan-20-onu i jej zastosowanie
EP3911331A4 (en) TETRAZOLONE SUBSTITUTED STEROIDS AND USE THEREOF
EP3993818A4 (en) CD38 BINDING AGENT AND RELATED USES
EP4079726A4 (en) NOVEL PYRIMIDINE DERIVATIVE AND USE THEREOF
EP3842441A4 (en) NEW MAGNESIUM SERINATE COMPOUND AND ITS USE
EP4028502A4 (en) N-ACYL-TYROSINE DERIVATIVES AND THEIR USE
EP3993874A4 (en) Cd38-binding agents and uses thereof
EP3999056A4 (en) PHARMACEUTICAL COMBINATION AND USE THEREOF
EP3919472A4 (en) DEZOCINE DERIVATIVE AND ITS MEDICAL USE
EP4031179A4 (en) PHARMACEUTICAL COMBINATION AND USE THEREOF
HK40068598A (zh) 泛酰半胱氨酸衍生物及其用途
HK40082821A (en) Fluoroalkyl-oxadiazoles and uses thereof
HK40080308A (en) 4-amino-imidazoquinoline compounds and use thereof
HK40068941A (en) Thiosemicarbazates and uses thereof
EP3938360A4 (en) CALIXCROWNS AND RELATED USES
HK40057160B (en) Pyrrolopyrimidine derivative and use thereof
HK40049643A (en) Terpinoid derivatives and uses thereof
HK40080153A (en) Novel compounds and their use
EP4031246A4 (en) CONNECTIONS AND USES THEREOF
HK40071687A (en) Cd38-binding agents and uses thereof

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20220215

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
REG Reference to a national code

Ref country code: DE

Ref legal event code: R079

Free format text: PREVIOUS MAIN CLASS: C07J0007000000

Ipc: A61K0031570000

Ref country code: DE

Ref legal event code: R079

Ref document number: 602020065298

Country of ref document: DE

Free format text: PREVIOUS MAIN CLASS: C07J0007000000

Ipc: A61K0031570000

A4 Supplementary search report drawn up and despatched

Effective date: 20230822

RIC1 Information provided on ipc code assigned before grant

Ipc: C07J 43/00 20060101ALI20230816BHEP

Ipc: C07J 41/00 20060101ALI20230816BHEP

Ipc: A61P 25/30 20060101ALI20230816BHEP

Ipc: A61P 25/14 20060101ALI20230816BHEP

Ipc: A61P 25/16 20060101ALI20230816BHEP

Ipc: A61P 25/08 20060101ALI20230816BHEP

Ipc: A61P 25/18 20060101ALI20230816BHEP

Ipc: A61P 25/28 20060101ALI20230816BHEP

Ipc: A61P 25/20 20060101ALI20230816BHEP

Ipc: A61P 25/24 20060101ALI20230816BHEP

Ipc: A61P 25/22 20060101ALI20230816BHEP

Ipc: A61P 25/00 20060101ALI20230816BHEP

Ipc: A61K 31/58 20060101ALI20230816BHEP

Ipc: A61K 31/57 20060101AFI20230816BHEP

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: DUKANG PHARMACEUTICALS, INC.

RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 31/57 20060101AFI20250623BHEP

Ipc: A61K 31/58 20060101ALI20250623BHEP

Ipc: A61P 25/00 20060101ALI20250623BHEP

Ipc: A61P 25/22 20060101ALI20250623BHEP

Ipc: A61P 25/24 20060101ALI20250623BHEP

Ipc: A61P 25/20 20060101ALI20250623BHEP

Ipc: A61P 25/28 20060101ALI20250623BHEP

Ipc: A61P 25/18 20060101ALI20250623BHEP

Ipc: A61P 25/08 20060101ALI20250623BHEP

Ipc: A61P 25/16 20060101ALI20250623BHEP

Ipc: A61P 25/14 20060101ALI20250623BHEP

Ipc: A61P 25/30 20060101ALI20250623BHEP

Ipc: C07J 41/00 20060101ALI20250623BHEP

Ipc: C07J 43/00 20060101ALI20250623BHEP

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: GRANT OF PATENT IS INTENDED

INTG Intention to grant announced

Effective date: 20250804

GRAS Grant fee paid

Free format text: ORIGINAL CODE: EPIDOSNIGR3

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE PATENT HAS BEEN GRANTED

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: TWI BIOTECHNOLOGY, INC.

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

REG Reference to a national code

Ref country code: CH

Ref legal event code: F10

Free format text: ST27 STATUS EVENT CODE: U-0-0-F10-F00 (AS PROVIDED BY THE NATIONAL OFFICE)

Effective date: 20260107

Ref country code: GB

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: CH

Ref legal event code: W10

Free format text: ST27 STATUS EVENT CODE: U-0-0-W10-W00 (AS PROVIDED BY THE NATIONAL OFFICE)

Effective date: 20260114

REG Reference to a national code

Ref country code: DE

Ref legal event code: R096

Ref document number: 602020065298

Country of ref document: DE

REG Reference to a national code

Ref country code: CH

Ref legal event code: Q17

Free format text: ST27 STATUS EVENT CODE: U-0-0-Q10-Q17 (AS PROVIDED BY THE NATIONAL OFFICE)

Effective date: 20260121

Ref country code: CH

Ref legal event code: R17

Free format text: ST27 STATUS EVENT CODE: U-0-0-R10-R17 (AS PROVIDED BY THE NATIONAL OFFICE)

Effective date: 20260121

REG Reference to a national code

Ref country code: IE

Ref legal event code: FG4D

RAP4 Party data changed (patent owner data changed or rights of a patent transferred)

Owner name: TWI BIOTECHNOLOGY, INC.

REG Reference to a national code

Ref country code: NL

Ref legal event code: FP

REG Reference to a national code

Ref country code: FI

Ref legal event code: FGE

P01 Opt-out of the competence of the unified patent court (upc) registered

Free format text: CASE NUMBER: UPC_APP_0002519_4011898/2026

Effective date: 20260126

REG Reference to a national code

Ref country code: DK

Ref legal event code: T3

Effective date: 20260302

REG Reference to a national code

Ref country code: PT

Ref legal event code: SC4A

Ref document number: 4011898

Country of ref document: PT

Date of ref document: 20260325

Kind code of ref document: T

Free format text: AVAILABILITY OF NATIONAL TRANSLATION

Effective date: 20260319

REG Reference to a national code

Ref country code: ES

Ref legal event code: FG2A

Ref document number: 3060711

Country of ref document: ES

Kind code of ref document: T3

Effective date: 20260327

REG Reference to a national code

Ref country code: GR

Ref legal event code: EP

Ref document number: 20260400284

Country of ref document: GR

Effective date: 20260407

REG Reference to a national code

Ref country code: SK

Ref legal event code: T3

Ref document number: E 48070

Country of ref document: SK